Clinical Study

Evaluation Of Cardiovascular And Bleeding Outcomes Post Percutaneous Coronary Intervention In Patients Undergoing Liver Transplant Evaluation

Posted Date: Mar 31, 2021

  • Investigator: Saad Ahmad
  • Specialties: Heart Disease, Liver Disease
  • Type of Study: Observational/Survey

Cardiovascular diseases involving coronary artery disease (CAD) contribute to a significant proprortion of morbidity and mortality in liver transplant recipients.(1) As the proportion of non alcoholic steatohepatitis (NASH) patients increase this representation is only set to increase given underlying concomitant risk factors with diabetes, obesity and smoking. As risk stratification tools are developed and ischemic evaluation reveal the burden of coronary artery disease is notable and requires revascularization.(2-8) Patients with cirrhosis and significant CAD undergoing coronary artery bypass grafting(CABG) are at higher risk for morbidity and mortality, thus deferred for percutaneous coronary revascularization (PCI) prior to listing. Although less invasive the challenges of PCI have been noted in literature with increase cardiovascular morbidity and mortality, and increased bleeding risk. Recent data published on similar topic had notable use of older stent generation.(9) However we aim to look at patients undergoing revascularization under the current drug eluting stent generation which have allowed for shorter dual antiplatelet therapy, with less stent thrombosis risk and reduced bleeding risk.(10-12)


• Adult Patients Older Than 18 Years. • Patients With Cirrhosis And Identified As End Stage Liver Disease. • Patients Getting Worked Up For Solid Organ Liver Transplant. • Patients With Angiographically Significant Coronary Artery Disease


End Stage Liver Disease, Coronary Artery Disease

For More Information:

Ahmed Souka

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.